a.lindholm

TL2 · Split

Contributes reviews on supplier material. Based in Split.

Joined 21 November 2024 · last posted 3d · groups: translators

79Posts here

1Topics

1Solutions

1.1kLikes received

1.9kLikes given

22Badges

225Days visited

4.7kPosts read

Recent activity

Full stream

Common supplements people ask about, assessed one at a time Replied, post #97 · Practice › Interactions · 25 Jul 2026 · 16 likes Practical answer on common supplements, since the theoretical one is upthread: do the simplest check first, write down the result, and only then decide whether the…
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one Replied, post #25 · Compounds › Oral incretins · 25 Jul 2026 · 0 likes Post #24 put the caveat in the right place and I want to underline it. Orforglipron is a small molecule rather than a peptide, which changes almost everything about how…
Distinguishing a red flag from an inconvenience — a second dataset Replied, post #9 · Sourcing › Red flags · 24 Jul 2026 · 4 likes Taking post #6 at face value and following it one step further. The most useful contribution to this subcategory is a resolved case written up with the resolution,…
Journal club: SUSTAIN 6 and its retinopathy signal Replied, post #100 · Evidence › Journal club · 22 Jul 2026 · 1 like The baseline characteristics table is the single most useful page for the questions that get asked here, because it tells you who the result applies to. The general…
Seven-day rolling means and why weekly readings mislead Replied, post #71 · Outcomes › Progress reports · 20 Jul 2026 · 1 like State the method before the numbers. Same scale, same time of day, same conditions — without that a series is a collection of readings rather than a measurement. I have…
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #64 · Analytics › Home & field testing · 8 Jul 2026 · 31 likes Building on post #61 rather than restating it. Where I have landed on consumer-accessible tests, having got it wrong once in public: the direction is clear, the…
Semaglutide formulation: what is in the licensed product besides the peptide Replied, post #26 · Compounds › Semaglutide · 2 Jul 2026 · 7 likes Sensible. I would want the same detail before I acted on it either.
Prescription requirements and telehealth models — a second dataset Replied, post #79 · Sourcing › Regulatory · 25 Jun 2026 · 1 like Prescription requirements and telehealth models has been discussed here with more heat than it deserves, mostly because two definitions have been in play the whole time.
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction Replied, post #10 · Compounds › Retatrutide · 21 Jun 2026 · 13 likes Hepatic effects: glucagon receptor agonism promotes hepatic fat oxidation, which is mechanistically plausible for benefit in metabolic liver disease. Whether that…
Publication patterns in the BPC-157 literature, examined Replied, post #10 · Compounds › Repair & healing peptides · 9 Jun 2026 · 16 likes I read post #6 twice before replying, because I had assumed the opposite. BPC-157's published evidence is overwhelmingly preclinical and mostly rodent. That is not a…
[2026 update] Regional warehouse stock versus direct despatch Replied, post #92 · Sourcing › Logistics · 5 Jun 2026 · 10 likes Document outcomes rather than forecasting them. A forecast in this category reads as reassurance and is not one. Where I would look next, rather than where I would stop.
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one… Replied, post #8 · Compounds › Retatrutide · 2 Jun 2026 · 5 likes Glycaemic effects improved rather than worsened in the diabetes work despite the glucagon component, which is the observation that resolves the apparent paradox. It is…